| Lovejoy Health Center | |
|
7 School St Ste 1 Albion ME 04910 | |
| (207) 437-9388 | |
| (207) 437-2557 |
| Full Name | Lovejoy Health Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 7 School St, Albion, Maine |
| Authorized Official Name and Position | Constance R Coggins (PRESIDENT/CEO) |
| Authorized Official Contact | 2078725610 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lovejoy Health Center 7 School St Ste 1 Albion ME 04910 Ph: (207) 437-9388 | Lovejoy Health Center 7 School St Ste 1 Albion ME 04910 Ph: (207) 437-9388 |
| NPI Number | 1922071745 |
|---|---|
| Provider Enumeration Date | 02/10/2006 |
| Last Update Date | 11/10/2014 |
| Medicare PECOS PAC ID | 5496726523 |
|---|---|
| Medicare Enrollment ID | O20050830000720 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922071745 | NPI | - | NPPES |
| 137970103 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | E58728 (Maine) | Primary |
| Provider Name | Dianne J Raymond |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447276886 PECOS PAC ID: 7416920129 Enrollment ID: I20040907000375 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Lois C Hamel Corson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730135039 PECOS PAC ID: 4880650613 Enrollment ID: I20041203000464 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Ann M. Schwink |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1164493136 PECOS PAC ID: 3173575289 Enrollment ID: I20050217000265 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Cynthia R Robertson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1316911787 PECOS PAC ID: 7012952278 Enrollment ID: I20050628000443 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Susan L Chase |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346349180 PECOS PAC ID: 4183616873 Enrollment ID: I20060120000660 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Nancy J Cooley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346282233 PECOS PAC ID: 2668484965 Enrollment ID: I20060706000042 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Deborah Daigle |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1154341139 PECOS PAC ID: 2769527787 Enrollment ID: I20100302000624 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Roy Miller |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700854361 PECOS PAC ID: 9032306212 Enrollment ID: I20101214000796 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Diane Zavotsky |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023128261 PECOS PAC ID: 8123099215 Enrollment ID: I20141104001286 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Dean Chamberlain |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922360411 PECOS PAC ID: 0840449419 Enrollment ID: I20150922000492 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Nancy R Glover |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659890473 PECOS PAC ID: 8325304934 Enrollment ID: I20171115001851 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Kaitlynn Helene Read |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063992501 PECOS PAC ID: 3678824521 Enrollment ID: I20180917001180 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Keiko Kurita |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306483961 PECOS PAC ID: 3678907904 Enrollment ID: I20191219001908 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
| Provider Name | Rebecca Marie Rice |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1841657343 PECOS PAC ID: 7214346311 Enrollment ID: I20210430001525 |
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago
News Archive
Capital Impact Partners announced today that it provided nearly $27.5 million in financing to projects delivering social impact for underserved communities across the U.S. during the second quarter of 2015. These projects are expected to increase access to health care services, dignified aging options, healthy food, and education for low-income people in seven states, while also creating nearly 250 jobs.
Micromedex clinical decision support and CareNotes® patient education content from Thomson Reuters will be integrated within the M2 Health Care Information System (HCIS).
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.
Incarcerated youth who have suffered head injuries, traumatic experiences and mental illness diagnoses are more likely to abuse multiple inhalants, according to researchers at Georgia State University and the University of North Carolina at Chapel Hill.
› Verified 2 days ago